SNORA70: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA70

NCBI ID: G26778

SNORA70

Other Name(s): small nucleolar RNA, H/ACA box 70 | Small nucleolar RNA, H/ACA box 70 | DXS648E | U70 | RNU70

SNORA70: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is H/ACA box 70 (SNORA70), which is expressed in high levels in various tissues and cell types. The H/ACA box 70 is composed of 195 nucleotides and is located within the 5' end of the RNA molecule.

SNORA70 is a potential drug target and biomarker due to its unique structure and function. Its H/ACA box 70 region is known for its ability to interact with various protein molecules, including histone deacetylases (HDACs), which are known to play a crucial role in the regulation of gene expression and DNA replication. The interaction between SNORA70 and HDACs raises the possibility that SNORA70 could be a drug target or biomarker for diseases associated with HDACs.

Drug Target Potential

SNORA70 has been identified as a potential drug target due to its interaction with HDACs. HDACs are known to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The inhibition of HDACs has been shown to promote the growth and survival of cancer cells and to improve the efficacy of neurodegenerative disease treatments.

The interaction between SNORA70 and HDACs makes it a promising target for small molecule inhibitors. Several studies have shown that SNORA70 can interact with HDACs and that inhibition of HDACs can lead to the downregulation of SNORA70. These findings suggest that SNORA70 may be an effective drug target for diseases associated with HDACs.

Biomarker Potential

SNORA70 has also been identified as a potential biomarker for various diseases. The expression of SNORA70 has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The levels of SNORA70 have also been shown to be associated with the severity of these diseases.

The potential use of SNORA70 as a biomarker makes it an attractive target for diagnostic and therapeutic applications. The downregulation of SNORA70 has been shown to improve the efficacy of neurodegenerative disease treatments and to enhance the sensitivity of cancer cells to chemotherapy. These findings suggest that SNORA70 may be a valuable biomarker for the diagnosis and treatment of various diseases.

Conclusion

SNORA70 is a small nucleolar RNA that has been identified as a potential drug target and biomarker. Its interaction with HDACs and its expression in various diseases make it a promising target for small molecule inhibitors. Further studies are needed to confirm the potential of SNORA70 as a drug target and biomarker and to develop effective therapies based on this target.

Protein Name: Small Nucleolar RNA, H/ACA Box 70

The "SNORA70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets